The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.
Open accessAbstract
Background Cannabis use disorder is associated with substantial morbidity and, after alcohol, is the most common drug bringing adolescents and adults into treatment. At present, there are no FDA-approved medications for cannabis use disorder. Combined pharmacologic interventions might be particularly useful in mitigating withdrawal symptoms and promoting abstinence.Objective The purpose of this study was to evaluate the safety and efficacy of dronabinol, a synthetic form of delta-9-tetrahydrocannabinol, a naturally occurring pharmacologically active component of marijuana, and lofexidine, an alpha-2 agonist, in treating cannabis dependence.Methods One hundred fifty six cannabis-dependent adults were enrolled and following a 1-week placebo lead-in phase 122 were randomized in a double-blind, placebo-controlled, 11-week trial. Participants were randomized to receive dronabinol 20mg three times a day and lofexidine 0.6 mg three times a day or placebo. Medications were maintained until the end of week eight, were then tapered over two weeks and patients were monitored off medications during the last study week. All participants received weekly motivational enhancement and relapse prevention therapy. Marijuana use was assessed using the timeline follow-back method.Results There was no significant difference between treatment groups in the proportion of participants who achieved 3 weeks of abstinence during the maintenance phase of the trial (27.9% for the medication group and 29.5% for the placebo group), although both groups showed a reduction over time.Conclusions Based on this treatment study, the combined intervention did not show promise as a treatment for cannabis use disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“dronabinol produced no greater effects than placebo when combined with lofexidine (an agonist of the α2-adrenergic receptor) for cannabis abstinence in a recent clinical trial 52.”
From Psychosocial and pharmacological interventions for the treatment of cannabis use disorder (2018) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
The Cannabis Youth Treatment (CYT) Study: Main findings from two randomized trials
Dennis, M. L., Godley, S. H., Diamond, G., Tims, F. M., Babor, T. F., Donaldson, J., Liddle, H. A., Titus, J. C., Kaminer, Y., Webb, C. P. M., et al. (2004) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2003.09.005 · Cited by 780
Timeline Follow-Back: A Technique for Assessing Self-Reported Alcohol Consumption
Sobell, L. C., & Sobell, M. B. (1992) · NSUWorks (Nova Southeastern University) · Cited by 779
Cannabinoids in medicine: A review of their therapeutic potential
Ben Amar, M. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.02.001 · Cited by 543
Topiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Johnson, B. A. (2007) · JAMA · doi:10.1001/jama.298.14.1641 · Cited by 542
(1992) · Humana Press eBooks · doi:10.1007/978-1-4612-0357-5 · Cited by 505
Psychotherapy and Pharmacotherapy for Ambulatory Cocaine Abusers
Carroll, K. M. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030013002 · Cited by 348
Marijuana withdrawal among adults seeking treatment for marijuana dependence.
Budney, A. J., Novy, P. L., & Hughes, J. R. (1999) · Addiction · doi:10.1046/j.1360-0443.1999.94913114.x · Cited by 348 · cited 2×
“” Marijuana withdrawal was assessed using the withdrawal checklist (Budney et al., 1999), a 10-item self-report instrument in which symptoms are rated either none, mild, moderate or severe (ranging respectively from 0-3) for a possible total score of 30.”
MethodSAFTEE: a technique for the systematic assessment of side effects in clinical trials.
Levine, J., & Schooler, N. (1986) · PubMed · Cited by 330
A Double-Blind Randomized Controlled Trial of N -Acetylcysteine in Cannabis-Dependent Adolescents
Gray, K. M., Carpenter, M. J., Baker, N. L., DeSantis, S. M., Kryway, E., Hartwell, K. J., McRae-Clark, A. L., & Brady, K. T. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010055 · Cited by 306
Cited by
Sorted by citations
Cannabis use and cannabis use disorder
Connor, J. P., Stjepanović, D., Le Foll, B., Hoch, E., Budney, A. J., & Hall, W. D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00247-4 · Cited by 552
Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective
Cooper, Z. D., & Craft, R. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.140 · Cited by 369
“Clinical trials investigating potential pharmacotherapies to treat CUD do not typically assess outcomes according to sex (recent studies include Allsop et al, 2014; Levin et al, 2016).”
BackgroundCannabis Addiction and the Brain: a Review
Zehra, A., Burns, J. A., Liu, C. K., Manza, P., Wiers, C. E., Volkow, N. D., & Wang, G. (2018) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-018-9782-9 · Cited by 277
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Pharmacotherapies for cannabis dependence.
Marshall, K., Gowing, L., Ali, R., & Le Foll, B. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub2 · Cited by 156
The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal
Brezing, C., & LEVIN, F. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.212 · Cited by 148
“Following the robust results of this human lab study, Levin et al (2016) took the combination of dronabinol and lofexidine to the clinic setting.”
BackgroundInfluentialSelf-citationHow effective and safe is medical cannabis as a treatment of mental disorders? A systematic review
Hoch, E., Niemann, D., von Keller, R., Schneider, M., Friemel, C. M., Preuss, U. W., Hasan, A., & Pogarell, O. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-00984-4 · Cited by 131
“[43] assessed abstinence (= 21 consecutive days), withdrawal, craving, and adverse events.”
BackgroundClinical management of cannabis withdrawal
Connor, J. P., Stjepanović, D., Budney, A. J., Foll, B. L., & Hall, W. (2021) · Addiction · doi:10.1111/add.15743 · Cited by 128
“This included trials of bupropion [52], FAAH inhibitor PF-04457845 for the majority of the withdrawal period [18], lithium [53], dronabinol and lofexidine [54], bupropion [55], nabiximols [56], extended-release zolpidem [57], guanfacine [58], escitalopram [59] and nabilone [60].”
MethodThe endocannabinoid system as a target for addiction treatment: Trials and tribulations
Sloan, M. E., Gowin, J. L., Ramchandani, V. A., Hurd, Y. L., & Foll, B. L. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.05.031 · Cited by 94
Consideration of sex and gender differences in addiction medication response
McKee, S. A., & McRae‐Clark, A. L. (2022) · Biology of Sex Differences · doi:10.1186/s13293-022-00441-3 · Cited by 67
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders
Galaj, E., & Xi, Z. (2019) · CNS Drugs · doi:10.1007/s40263-019-00664-w · Cited by 69
Pharmacotherapy for the Treatment of Cannabis Use Disorder
Kondo, K. K., Morasco, B. J., Nugent, S. M., Ayers, C. K., O'Neil, M. E., Freeman, M., & Kansagara, D. L. (2020) · Annals of Internal Medicine · doi:10.7326/m19-1105 · Cited by 63
Mendes, F. R., Costa, C. D. S., Wiltenburg, V. D., Morales-Lima, G., Fernandes, J. A. B., & Filev, R. (2022) · Addiction Neuroscience · doi:10.1016/j.addicn.2022.100025 · Cited by 67
Therapeutic potential of medicinal marijuana: an educational primer for health care professionals
Mouhamed, Y., Vishnyakov, A., Qorri, B., Sambi, M., Frank, S. M. S., Nowierski, C., Lamba, A., Bhatti, U., & Szewczuk, M. R. (2018) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s158592 · Cited by 59
Brezing, C., Choi, C. J., Pavlicová, M., Brooks, D., Mahony, A. L., Mariani, J. J., & LEVIN, F. R. (2018) · American Journal on Addictions · doi:10.1111/ajad.12660 · Cited by 49
“Of the 156 participants enrolled in the double-blind study, 122 participants were randomized to receive either placebo or active medication (dronabinol and lofexidine) for 11 weeks in an outpatient clinic setting.(3) A total of 62 participants completed 12 weeks of the study and completed QLES-Q-SF scores at week 12.”
BackgroundMethodInfluentialSelf-citationLee, D. C., Schlienz, N. J., Peters, E. N., Dworkin, R. H., Turk, D. C., Strain, E. C., & Vandrey, R. G. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.10.020 · Cited by 49
Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies
Sloan, M. E., Grant, C. W., Gowin, J. L., Ramchandani, V. A., & Foll, B. L. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0081-z · Cited by 47
Spanagel, R., & Bilbao, A. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108680 · Cited by 43
“, 2018), followed by 18% drug dependent patients (2 RCTs (n = 182)) (Bisaga et al., 2015; Levin et al., 2016), 6% cancer patients (n = 64), (Meiri et al.”
BackgroundInfluentialPharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis
Bahji, A., Meyyappan, A. C., Hawken, E. R., & Tibbo, P. G. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103295 · Cited by 48
Lucatch, A. M., Coles, A. S., Hill, K. P., & George, T. P. (2018) · Current Addiction Reports · doi:10.1007/s40429-018-0214-y · Cited by 40
Pharmacotherapies for cannabis dependence
Nielsen, S., Gowing, L., Sabioni, P., & Le Foll, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub3 · Cited by 96
Quetiapine treatment for cannabis use disorder
Mariani, J. J., Pavlicová, M., Choi, C. J., Basaraba, C. N., Carpenter, K. M., Mahony, A. L., Brooks, D. J., Bisaga, A. M., Naqvi, N. H., Nunes, E. V., et al. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108366 · Cited by 38
Self-citationPsychosocial and pharmacological interventions for the treatment of cannabis use disorder
Sabioni, P., & Le Foll, B. (2018) · F1000Research · doi:10.12688/f1000research.11191.1 · Cited by 37
“…cannabis withdrawal symptoms and increased retention in treatment when compared with placebo in early studies 51 , dronabinol produced no greater effects than placebo when combined with lofexidine (an agonist of the α 2-adrenergic receptor) for cannabis abstinence in a recent clinical trial 52 .”
BackgroundWilson, J., Dobson, O., Langcake, A., Mishra, P., Bryant, Z., Leung, J., Dawson, D., Graham, M., Teesson, M., Freeman, T. P., et al. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00015-5 · Cited by 34
Interventions for cannabis use disorder
Winters, K. C., Mader, J., Budney, A. J., Stanger, C., Knapp, A. A., & Walker, D. D. (2020) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2020.11.002 · Cited by 34
Greenwald, M. K. (2018) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.08.003 · Cited by 33
“Regarding cannabis use disorder, one study found that lofexidine reduced marijuana relapse-like behavior in a human laboratory model (Haney et al., 2008) but was not generally effective, when combined with oral THC, for reducing outpatient cannabis use (Levin et al., 2016).”
BackgroundThe effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration
Schlienz, N. J., Lee, D. C., Stitzer, M. L., & Vandrey, R. G. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.02.022 · Cited by 31
Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial
McRae‐Clark, A. L., Gray, K. M., Baker, N. L., Sherman, B. J., Squeglia, L. M., Sahlem, G. L., Wagner, A. M., & Tomko, R. L. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109111 · Cited by 30
Impact of cannabis legalization on treatment and research priorities for cannabis use disorder
Sahlem, G. L., Tomko, R. L., Sherman, B. J., Gray, K. M., & McRae‐Clark, A. L. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1465398 · Cited by 32
“…laboratory studies (Budney, Vandrey, Hughes, Moore, & Bahrenburg, 2007; Haney et al., 2004; 2008; 2013; Vandrey et al., 2013) and clinical trials (Levin et al., 2011, 2016), have consistently shown suppression of withdrawal, but have been ineffective in increasing cannabis abstinence among…”
BackgroundLintzeris, N., Mills, L., Dunlop, A. J., Copeland, J., McGregor, I. S., Bruno, R., Kirby, A. C., Montebello, M. E., Hall, M., Jefferies, M., et al. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108220 · Cited by 29
Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers
Haney, M., Cooper, Z. D., Bedi, G., Herrmann, E., Comer, S. D., Reed, S. C., Foltin, R. W., & Levin, F. R. (2019) · Addiction Biology · doi:10.1111/adb.12621 · Cited by 31
Self-citationWatanabe, A. H., Navaravong, L., Sirilak, T., Prasitwarachot, R., Nathisuwan, S., Page, R. L., II, & Chaiyakunapruk, N. (2021) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2021.03.013 · Cited by 27
Werneck, M. A., Kortas, G. T., de Andrade, A. G., & Castaldelli-Maia, J. M. (2018) · CNS Drugs · doi:10.1007/s40263-018-0577-6 · Cited by 25
“Four trials exclusively selected cannabis-dependent users [29, 31, 43, 45], while the others also comprised non-dependent cannabis users.”
InfluentialTrexler, K. R., Eckard, M. L., & Kinsey, S. G. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.12.009 · Cited by 25
“Additionally, combinations of cannabinoid and non-cannabinoid therapies are effective in attenuating some symptoms of withdrawal, but enhance other side effects, such as withdrawal-induced anorexia and sedation (Haney et al. 2008; Levin et al. 2016).”
BackgroundNon-abstinent treatment outcomes for cannabis use disorder
LEVIN, F. R., Mariani, J. J., Choi, C. J., Basaraba, C. N., Brooks, D. J., Brezing, C., & Pavlicová, M. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108765 · Cited by 22
Self-citationPsychosocial and Pharmacological Interventions for the Treatment of Cannabis Use Disorder
Sabioni, P., & Foll, B. L. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.17202 · Cited by 22
Treatments for Cannabis Use Disorder across the Lifespan: A Systematic Review
Ghafouri, M., da Costa, S. C., Dehnavi, A. Z., Gold, M. S., & Rummans, T. A. (2024) · Brain Sciences · doi:10.3390/brainsci14030227 · Cited by 20
“Six clinical trials examined treatment for cannabis use disorder in older adults, with three focusing on pharmacological interventions (lithium, nabiximols, and dronabinol) [33,36,37] and three examining non-pharmacological treatments for this age group.”
BackgroundSahlem, G. L., Kim, B., Baker, N. L., Wong, B. L., Caruso, M. A., Campbell, L. A., Kaloani, I., Sherman, B. J., Ford, T. J., Musleh, A. H., et al. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.111035 · Cited by 22
Cannabis Addiction and the Brain: a Review
Zehra, A., Burns, J. A., Liu, C. K., Manza, P., Wiers, C. E., Volkow, N. D., & Wang, G. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.17204 · Cited by 18
Efficiency of Inhaled Cannabidiol in Cannabis Use Disorder: The Pilot Study Cannavap
Cleirec, G., Desmier, E., Lacatus, C., Lesgourgues, S., Braun, A., Peloso, C., & Obadia, C. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.899221 · Cited by 18
Screening Medications for the Treatment of Cannabis Use Disorder
Panlilio, L. V., Justinová, Z., Trigo, J. M., & Foll, B. L. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.02.005 · Cited by 18
Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents
Nielsen, S., Sabioni, P., Gowing, L., & Foll, B. L. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_258 · Cited by 17
Nicotine patch for cannabis withdrawal symptom relief: a randomized controlled trial
Gilbert, D. G., Rabinovich, N. E., & McDaniel, J. T. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05476-1 · Cited by 16
“In contrast, a recent randomized clinical trial found that the combination of lofexidine and dronabinol (a partial cannabinoid receptor agonist) to be no more efficacious than placebo in individuals with CUD (Levin et al. 2016).”
BackgroundVuilleumier, C., Scherbaum, N., Bonnet, U., & Roser, P. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.867878 · Cited by 16
Open-label pilot study of injectable naltrexone for cannabis dependence
Notzon, D. P., Kelly, M. A., Choi, C. J., Pavlicová, M., Mahony, A. L., Brooks, D. J., Mariani, J. J., & LEVIN, F. R. (2018) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2017.1423321 · Cited by 15
Self-citationCannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth?
Thomsen, K. R., Thylstrup, B., Kenyon, E. A., Lees, R., Baandrup, L., Ewing, S. W. F., & Freeman, T. P. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.11.033 · Cited by 15
Martin, E. L., Doncheck, E. M., Reichel, C. M., & McRae‐Clark, A. L. (2021) · Neurobiology of Stress · doi:10.1016/j.ynstr.2021.100364 · Cited by 14
Cui, Q., Bian, R., Xu, F., Li, Q., Wang, W., & Bian, Q. (2021) · Studies in natural products chemistry · doi:10.1016/b978-0-12-819487-4.00016-1 · Cited by 14
Imperio, C. G., LEVIN, F. R., & Martínez, D. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20231023 · Cited by 15
Self-citationNeuronal nicotinic acetylcholine receptors mediate ∆ 9 ‐THC dependence: Mouse and human studies
Donvito, G., Muldoon, P. P., Jackson, K. J., Ahmad, U., Zaveri, N. T., McIntosh, J. M., Chen, X., Lichtman, A. H., & Damaj, M. I. (2018) · Addiction Biology · doi:10.1111/adb.12691 · Cited by 13
A Systematic Review of Medical Cannabinoids Dosing in Human
Campos, D. A., Mendivil, E. J., Romano, M., García, M., & Martínez, M. E. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.10.003 · Cited by 14
Pharmacotherapies for cannabis use disorder
Spiga, F., Parkhouse, T., Tang, V. M., Savović, J., Foll, B. L., & Nielsen, S. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub4 · Cited by 12
Pressman, P., Hayes, A., Hoeng, J., Latino, D., Mazurov, A., Schlage, W., & Rana, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061540 · Cited by 11
Gabapentin attenuates somatic signs of precipitated THC withdrawal in mice
Eckard, M. L., & Kinsey, S. G. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108554 · Cited by 10
Beyond monoamines: II. Novel applications for PET imaging in psychiatric disorders
Royse, S. K., Lopresti, B. J., Mathis, C. A., Tollefson, S., & Narendran, R. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15657 · Cited by 10
Mills, L., Dunlop, A. J., Montebello, M. E., Copeland, J., Bruno, R., Jefferies, M., McGregor, I. S., & Lintzeris, N. (2022) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-022-00493-z · Cited by 9
“Though promising, replication of these results in additional randomised trials is necessary, and as yet there are still no FDA-approved pharmacotherapies for CUD [22].”
BackgroundInfluentialManagement of withdrawal from alcohol and other drugs
Lintzeris, N., Sunjic, S., Demirkol, A., Branezac, M., Ezard, N., Siefried, K. J., Acheson, L. S., Bascombe, F., Tremonti, C., & Haber, P. (2019) · doi:10.57022/mjjp9930 · Cited by 9
Sinclair, J., Kalk, N. J., Kaar, S. J., Agabio, R., Arunogiri, S., Bisaga, A. M., Chesney, E., Daly, C., Dewhurst, J., Freeman, T. P., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251399593 · Cited by 10
“Four RCTs have investigated cannabinoid receptor partial agonists as cannabis-substi-tution therapy (Levin et al., 2011, 2016; Lintzeris et al., 2019; Trigo et al., 2018) (Ib), with mixed results on withdrawal, retention and abstinence.”
Self-citationMartin, E. L., & McRae‐Clark, A. L. (2020) · Current Addiction Reports · doi:10.1007/s40429-020-00342-8 · Cited by 8
Alayoubi, M., Henry, B. A., Cahill, C. M., & Cooper, Z. D. (2024) · Drugs · doi:10.1007/s40265-024-02098-1 · Cited by 7
“…use in a laboratory model of relapse after three days of forced abstinence with continuous measure of cannabis self-administration [41], whereas the outpatient study with treatment-seekers required that participants self-initiate abstinence prior to assessing relapse (continued abstinence) [74].”
InfluentialLile, J. A., Alcorn, J. L., Hays, L. R., Kelly, T. H., Stoops, W. W., Wesley, M. J., & Westgate, P. M. (2021) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000464 · Cited by 7
Gharbi, K. A., Bonomo, Y. A., & Hallinan, C. M. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20054087 · Cited by 7
“Two double-blinded RCTs in large populations (n = 156,122) of longer duration (9, 10 weeks) were conducted [54,56].”
BackgroundInfluentialCannabinoids for Substance Use Disorder Treatment: What Does the Current Evidence Say?
Fernandes, J. A. B., Filev, R., & Fidalgo, T. M. (2023) · Cannabis and Cannabinoid Research · doi:10.1089/can.2023.0065 · Cited by 6
“24,26,28 While the clinical evidence supporting the use of plant-based CBD + THC extracts for treating SUD is still limited, recent observational studies indicate that the synergistic effects of cannabinoids and other compounds present in cannabis may improve treatment retention and reduce…”
InfluentialHuman Laboratory Models of Cannabis Use Disorder
Arout, C. A., Herrmann, E. S., & Haney, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-90365-1_9 · Cited by 6
The Treatment of Cannabis Use Disorder
Danovitch, I., & Gorelick, D. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54856-4.00007-9 · Cited by 5
Preto, M. C., Kortas, G. T., Blaas, I. K., Lassi, D. L. S., Campos, M. W., Torales, J. C., Ventriglio, A., Périco, C. D. A.-M., de Andrade, A. G., & Castaldelli-Maia, J. M. (2023) · International Review of Psychiatry · doi:10.1080/09540261.2023.2231540 · Cited by 4
“Cooper et al. (2013) had a majority of black patients, while Levin et al. (2016) had an almost equal distribution of black and white patients in both the placebo and intervention groups.”
Hudson, D., Howarth, N., Idalsoaga, F. J., Song, Y. N., Islam, A. H., Theiventhiran, S., Díaz, L. A., & Arab, J. P. (2024) · Current Hepatology Reports · doi:10.1007/s11901-024-00630-1 · Cited by 4
“Synthetic Cannabinoids RCTs involving dronabinol (synthetic delta-9-tetrahydrocannabinol) did not show any differences in abstinence rates between treatment with 20 mg twice daily or three times daily over 8 weeks versus placebo [152, 153].”
Sahlem, G. L., Kim, B., Baker, N. L., Wong, B. L., Caruso, M. A., Campbell, L. A., Kaloani, I., Sherman, B. J., Ford, T. J., Musleh, A. H., et al. (2023) · medRxiv · doi:10.1101/2023.07.10.23292461 · Cited by 4
“Notably, no pharmacotherapy trial (including full agonist therapy 11,65 ) has observed a between-group change in craving over the course of treatment using the MCQ-SF, even when finding a clinical effect.”
Cannabinoids for the treatment of cannabis abuse disorder
Rodríguez, A., & Zavala, C. (2018) · Medwave · doi:10.5867/medwave.2018.06.7286 · Cited by 3
Cannabinoid Drugs in Mental Health Disorders
Kloiber, S. M., Matheson, J., Kim, H. K., & Foll, B. L. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_465-1 · Cited by 3
Cannabiskonsum und Cannabiskonsumstörungen
Hoch, E., & Preuss, U. W. (2024) · Der Nervenarzt · doi:10.1007/s00115-024-01722-5 · Cited by 2
Cannabinoids in disorders of gut-brain interaction and gastrointestinal motility
Arboleda, M. F., Prosk, E., Watier, A., & Schmulson, M. J. (2021) · NeuroGastroLATAM Reviews · doi:10.24875/ngl.20000021 · Cited by 2
Nizama-Valladolid, M. (2017) · ACTA MEDICA PERUANA · doi:10.35663/amp.2017.343.410 · Cited by 2
Wirksamkeit, Verträglichkeit und Sicherheit von medizinischem Cannabis
Hoch, E., Schneider, M., von Keller, R., Bonnet, U., Falkai, P., Hasan, A., Häuser, W., Hinz, B., Jakob, L., Kabisch, J., et al. (2018) · Springer eBooks · doi:10.1007/978-3-662-57291-7_4 · Cited by 2
Empirical Analysis of the Volatility of Stock Market Based on the Improved GARCH Model
祝, 人. (2020) · Advances in Applied Mathematics · doi:10.12677/aam.2020.92017 · Cited by 2
Pharmacotherapy for Cannabis Use Disorder: Preclinical and Clinical Models
Bedillion, M. F., Moore, C. F., Weerts, E. M., Arout, C. A., Harris, H. M., & Haney, M. (2025) · Current topics in behavioral neurosciences · doi:10.1007/7854_2025_598 · Cited by 1
New Horizons in the Development of Treatments for Substance Use Disorders
Mariani, J. J., & LEVIN, F. R. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20260362 · Cited by 1
Self-citationCannabinoids to Treat Cannabis Use Disorders
Brezing, C., & LEVIN, F. R. (2018) · Springer eBooks · doi:10.1007/978-3-319-90365-1_19 · Cited by 1
Self-citationCannabis Use Disorders in Primary Care: Screening and Treatment Suggestions
Turner, S., Nader, M., & Graves, L. E. (2017) · Medical Research Archives · doi:10.18103/mra.v5i7.1309
Uso medicinal de la marihuana: la discusión pendiente - Réplica
Nizama-Valladolid, M. (2018) · ACTA MEDICA PERUANA · doi:10.35663/amp.2017.344.472
“Los medicamentos derivados de los cannabinoides (dronabinol y nabilona) están indicados como paliativos de la emesis, crisis convulsivas y dolor neuropático crónico basado en estudios aleatorizados [5].”
BackgroundFerreira, J. V., Correa, L. C., da Costa, D. C., & Hage-Melim, L. I. D. S. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82184
“6 mg three times a day), with 40% of patients presenting dizziness and fatigue [69].”
BackgroundThe Research Progress of Treatment of Several Mental Disorders Using Cannabis Drugs (THC and CBD)
周, 小. (2020) · Advances in Clinical Medicine · doi:10.12677/acm.2020.102020
Cannabis Use Disorder and Its Treatment
Budney, A. J., & Sofis, M. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-36391-8_12
Chapter 17. Treatment of Cannabis-Related Disorders
Brezing, C., Mitra, S., & LEVIN, F. R. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615373970.kb17
Self-citationCannabisarznei zur Behandlung psychischer Störungen
Hoch, E., Preuss, U. W., & Pogarell, O. M. (2020) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-020-1271-z
Treatment of Co-occurring Psychiatric Disorders and Cannabis Use in the Outpatient Setting
Veligati, S., & Ritvo, A. D. (2022) · Psychiatry update · doi:10.1007/978-3-031-04874-6_10
Ferreira, J. V., Chaves, G. A., Batista, M. A., Correia, L. C., de Souza, L. R., da Costa, D. C., Barcelos, M. P., da Silva, C. H. T. D. P., Taft, C. A., & Hage-Melim, L. I. D. S. (2022) · Engineering materials · doi:10.1007/978-3-031-07622-0_16
Cannabinoid Drugs in Mental Health Disorders
Kloiber, S. M., Matheson, J., Kim, H. K., & Foll, B. L. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_465
Gorodetzky, C. W., Gullo, K. L., & Fishman, M. J. (2023) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780197618431.013.21
Gabapentinoids for the treatment of cannabis use disorder: A focus on human laboratory research
Lile, J. A., Stoops, W. W., & Wesley, M. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89862-1.00042-8
Wolinsky, D. I., & Vandrey, R. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89862-1.00037-4
Disorders Due to Substance Use: Cannabis
Cousijn, J., Compton, W. M., & LEVIN, F. R. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_161-1
Self-citationLaurenz, L. J., & Thomasius, R. (2023) · Springer eBooks · doi:10.1007/978-3-662-65267-1_25
Mills, L., Dunlop, A. J., Montebello, M. E., Copeland, J., Bruno, R., Jefferies, M., McGregor, I. S., & Lintzeris, N. (2022) · Figshare · doi:10.6084/m9.figshare.21303200
Chapter 54. Treatment of Substance Use Disorders
Sherman, B. J., Hartwell, K. J., McRae‐Clark, A. L., Herron, A., & Brady, K. T. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as54
Disorders due to Substance Use: Cannabis
Cousijn, J., Compton, W. M., & LEVIN, F. R. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_161
Self-citationChapter 4. Cannabis and Cannabinoids
Rossopoulos, T., & Marienfeld, C. B. (2025) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894550862.lg04
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517185
Bilbao, A., & Spanagel, R. (2022) · Figshare · doi:10.6084/m9.figshare.20517173
Metadata
- Authors
- Levin, F. R., Mariani, J. J., Pavlicova, M., Brooks, D., Glass, A., Mahony, A., Nunes, E. V., Bisaga, A., Dakwar, E., Carpenter, K. M., Sullivan, M. A., & Choi, J. C.
- Affiliations
- New York State Psychiatric Institute (US)
- Corresponding author
- Levin, Frances R.
- ORCID
- Venue
- Drug and Alcohol Dependence
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 159
- Pages
- 53-60
- ISSN
- 0376-8716 (ISSN-L)
- PMC
- PMC4729291
- OpenAlex
- W2174050801
- Cited by
- 109
- References
- 34
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 8 · 2023: 10 · 2022: 18 · 2021: 15 · 2020: 10 · 2019: 9 · 2018: 21 · 2017: 5 · 2016: 1
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Drug and Alcohol Dependence (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Public Health Service (K02 000465)
- National Institute on Drug Abuse (K02DA000465, P50 DA-09236, P50DA009236, K24DA029647)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- cannabis use disorder, dronabinol, lofexidine, delta-9-tetrahydrocannabinol, alpha-2 adrenergic agonists, combined pharmacotherapy, abstinence, withdrawal symptoms, motivational enhancement therapy, relapse prevention, treatment efficacy
- MeSH terms
- Adolescent, Adult, Marijuana Abuse, Clonidine, Double-Blind Method, Female, Humans, Male, Middle Aged, Narcotic Antagonists, Substance Withdrawal Syndrome, Dronabinol, Drug Monitoring, Secondary Prevention, Cannabinoid Receptor Agonists, Craving
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
